Skip to main content

Table 1 Patient characteristics of the discovery cohort

From: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Characteristics

No. (%)

No. of patients

519

Median age, years (range)

64 (18–92)

Sex

 Male

300 (57.8)

 Female

219 (42.2)

Cancer type

 Bladder cancer

27 (5.2)

 Esophagogastric cancer

40 (7.7)

 Head and neck cancer

10 (1.9)

 Melanoma

148 (28.5)

 Non-small-cell lung cancer

294 (56.6)

Drug class

 CTLA-4, monotherapy

142 (27.4)

 PD-(L)1, monotherapy

320 (61.7)

 CTLA-4 + PD-(L)1, combination therapy

57 (11.0)

Best overall response

 CR/PR

126 (24.3)

 SD

137 (26.4)

 PD

252 (48.6)

 NE

4 (0.8)

Durable clinical benefit

 DCB

165 (31.8)

 NDB

330 (63.6)

 NE

24 (4.6)

Median TMB, Mutation/Mb (IQR)

7.14 (3.77–13.24)

TET1 status

 Mutant

23 (4.4)

 Wildtype

496 (95.6)

  1. Abbreviations: CR complete response, CTLA-4 cytotoxic T-cell lymphocyte-4, DCB durable clinical benefit, IQR interquartile range, Mb megabase, NDB no durable benefit, NE not evaluable, PD progressive disease, PD-(L)1 programmed cell death-1 or programmed death-ligand 1, PR partial response, SD stable disease, TMB tumor mutational burden